ArticleNature materials2024
Inulin-gel-based oral immunotherapy remodels the small intestinal microbiome and suppresses food allergy.
Abstract read
In one paragraph
Article in Nature materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Dynamic feedback BacGuard anchors microbial metabolism to host symbiosis in real-time ulcerative colitis therapy.Bioactive materials · 2026Article
- Microbiota and anaphylaxis: emerging insights into immune regulation and clinical implications.Current opinion in allergy and clinical immunology · 2026Review
- Diet-Microbiome-Immune Interactions at the Gut Mucosa in Food Allergy: Mechanisms, Gaps, and Therapeutic Implications.Allergy · 2026Review
- Immunomodulatory Function of Soluble Dietary Fiber: Toward Application for Prevention and Treatment of Food Allergies.Current allergy and asthma reports · 2026Review
- A transferable gut microbiota-bile acid pathway programs nanomedicine pharmacokinetics and therapeutic response.Nature materials · 2026Article
- Mesoporous polydopamine and inulin hydrogel for improved deoxynojirimycin effect in type 2 diabetes mellitus management.Materials today. Bio · 2026Article
- Inulin-Butyrate Nanogel for Modulation of Gut Microbiome, Intestinal Barrier, and Regulatory T-Cells in Colitis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Inulin-Based Oral Chemotherapy Modulates Gut Microbiota and Immune Microenvironment through Inhibition of Neutrophil Extracellular Trap Formation for Improving Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Oral colon targeted curcumin-based nanocomposite inulin hydrogel for alleviating intestinal inflammation and dysbiosis.Journal of nanobiotechnology · 2026Article
- Bioengineering Interventions to Enhance the Capacity of the Gut Microbiota in Controlling Food Allergies.Life (Basel, Switzerland) · 2026Review
- The Plasticene Paradigm: Microplastics, Gut Dysbiosis, and Food Allergy - A Critical Commentary.Journal of asthma and allergy · 2026Review
- Context-dependent roles of the gut microbiome in food allergy tolerance versus sensitization.Gut microbes · 2025Review
- Impact of Periodontal Host-Modulation Therapies on Oral-Gut Microbiome Axis in Periodontitis Patients with Hematological Diseases: A Narrative Review.Life (Basel, Switzerland) · 2025Review
- Diet Components, Immune Function and IgE-Mediated Food Allergy.Nutrients · 2025Review
- DNA-utilization loci enable exogenous DNA metabolism in gut Bacteroidales.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Improved prebiotic-based "shield" equipped probiotics for enhanced colon cancer therapy by polarizing M1 macrophages and regulating intestinal microbiota.Acta pharmaceutica Sinica. B · 2025Article
- Co-delivery of targeted hypoallergens and resiquimod powders using silk fibroin microneedles for effective allergen-specific immunotherapy.Theranostics · 2025Article
- Gut-lung axis in allergic asthma: microbiota-driven immune dysregulation and therapeutic strategies.Frontiers in pharmacology · 2025Review
- Immunomodulatory and anti-inflammatory effects of agave fructans in atopic dermatitis: gut microbiota and short-chain fatty acid implication.Frontiers in immunology · 2025Article
- Regulation of immune responses to food by commensal microbes.Immunological reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Kai Han *Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-5370-4296
Fang Xie *Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Olamide AnimasahunBiointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-4032-3619
Minal NenwaniBiointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
Sho KitamotoDivision of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Yeji KimDivision of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
May Thazin PhooDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-9411-621X
Jin XuDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Fulei WuchuBiointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-7772-7449
Kehinde OmolojaBiointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0001-6446-984X
Abhinav AchrejaBiointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-1773-6490
Srinadh ChopparaBiointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
Zhaoheng LiGraduate Program in Biostatistics, University of Washington, Seattle, WA, USA.
Wang GongDepartments of Head and Neck Surgery and of Cancer Biology, the University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Young Seok ChoDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-1338-3170
Hannah DobsonDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-1246-880X
Jinsung AhnDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Xingwu ZhouDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Xuehui HuangDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Xinran AnDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Alexander KimDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Yao XuDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Qi WuDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-2550-3769
Soo-Hong LeeDepartment of Biomedical Engineering, Dongguk University, Seoul, Republic of Korea.
Jessica J O'KonekMary H. Weiser Food Allergy Center, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-1455-0586
Yuying XieDepartment of Computational Mathematics, Science and Engineering, Michigan State University, East Lansing, MI, USA.
Yu Leo LeiDepartments of Head and Neck Surgery and of Cancer Biology, the University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Nobuhiko KamadaDivision of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Deepak NagrathBiointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-8999-2282
James J MoonDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA. moonjj@umich.edu.ORCID 0000-0003-2238-2372
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2MRegional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3MRestoring the Immunogenicity of Head and Neck CancerR01DE026728 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Yu Leo Lei, James J. Moon · 2018 to 2026
$4.3MThe role of IL-1ß-inducing pathobionts in the pathogenesis of Crohn’s diseaseR01DK108901 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Nobuhiko Kamada · 2017 to 2026
$3.8MMathematical Model-Based Optimization of CRT Response in IschemiaR01HL166508 · NHLBI · CALIFORNIA MEDICAL INNOVATIONS INSTITUTE · PI GHASSAN S KASSAB, Lik Chuan Lee · 2023 to 2026
$3.1MEngineered Nano-formulations for STING ActivationR01DE031951 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yu Leo Lei, James J. Moon · 2022 to 2026
$3.1MNew Engineering Strategy for Harnessing Immune System against Head and Neck CancerR01DE030691 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LEI, YU LEO, MOON, JAMES J. · 2021 to 2025
$2.9MTargeting Stromal Influences on BCKA Addiction in PDAC TumorsR01CA271369 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE, Deepak Nagrath · 2022 to 2026
$2.8MBiomaterials for modulating the gut microbiome for immune activationR01CA271799 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI James J. Moon, Deepak Nagrath · 2022 to 2026
$2.7MAdvancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral PremalignancyU01DE033330 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Steven Bennett Chinn, Yu Leo Lei · 2023 to 2026
$2.7MCellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6MNovel nano-vaccine technology for inducing immunity against gliomasR01NS122536 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, MOON, JAMES J. · 2021 to 2025
$2.6MNCI NIH HHS P30 CA046592NCI NIH HHS R01 CA204969NCI NIH HHS R01 CA210273NCI NIH HHS R01 CA222251NCI NIH HHS R01 CA227622NCI NIH HHS R01 CA271369NCI NIH HHS R01 CA271799NHLBI NIH HHS R01 HL166508NIAID NIH HHS HHSN272201300006CNIDCR NIH HHS R01 DE026728NIDCR NIH HHS R01 DE030691NIDCR NIH HHS R01 DE031951NIDCR NIH HHS U01 DE033330NIDDK NIH HHS P30 DK020572NIDDK NIH HHS R01 DK108901NIDDK NIH HHS R01 DK125087NIGMS NIH HHS T32 GM145304NINDS NIH HHS R01 NS122536
Abstract
Despite the potential of oral immunotherapy against food allergy, adverse reactions and loss of desensitization hinder its clinical uptake. Dysbiosis of the gut microbiota is implicated in the increasing prevalence of food allergy, which will need to be regulated to enable for an effective oral immunotherapy against food allergy. Here we report an inulin gel formulated with an allergen that normalizes the dysregulated ileal microbiota and metabolites in allergic mice, establishes allergen-specific oral tolerance and achieves robust oral immunotherapy efficacy with sustained unresponsiveness in food allergy models. These positive outcomes are associated with enhanced allergen uptake by antigen-sampling dendritic cells in the small intestine, suppressed pathogenic type 2 immune responses, increased interferon-γ
Indexed as
AllergensFood HypersensitivityGastrointestinal MicrobiomeGelsIntestine, SmallInulinAdministration, OralAnimalsDesensitization, ImmunologicImmunotherapyMiceAllergensGelsInulin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.